Drug intelligence / Profile preview

NST-12

Development stage: Preclinical
Lead developer: Novasenta
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NST-12 is a preclinical antibody-based therapeutic being developed by Novasenta. It is designed to target a novel, undisclosed immune cell target to modulate immune activity within the tumor microenvironment (TME) and in immune-mediated diseases. The drug was identified using Novasenta's proprietary discovery platform, which analyzes the TME to find new therapeutic targets. NST-12 aims to regulate immune cell function to treat cancer and inflammatory conditions. As of the latest company updates, the program is in the preclinical stage of development.

Beyond the preview

Go deeper on NST-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NST-12.

Explore the full profile